Plain-English translation of NCT07527156 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing whether a ketone supplement called D-3-hydroxybutyrate (3-OHB) can help people with severely weakened hearts who are in acute crisis. The medication is delivered continuously through a thin tube placed in your nose and down to your stomach for 36 hours. Researchers will carefully monitor your blood levels and adjust the dose to keep it in a safe, therapeutic range.
When the heart is severely weakened and in crisis, it struggles to pump enough blood to the body. This medication works by providing an alternative fuel source that the heart can use more efficiently, potentially reducing strain and helping it recover.
You likely qualify if…
You likely don't qualify if…
If you join this trial, a thin feeding tube will be placed through your nose into your stomach, and the ketone supplement will flow continuously for 36 hours. Medical staff will draw small blood samples every 1 to 3 hours to check your ketone levels and adjust the dose as needed. Throughout the study, doctors will monitor your heart rhythm, liver function, and how well your stomach tolerates the treatment.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
Czechia
Phase
Post-approval monitoring
Sponsor
Institute for Clinical and Experimental Medicine
Enrollment target
~12 participants
Started
April 2026
Primary completion
March 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Marek Sramko, MD, PhD
Institute for Clinical and Experimental Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.